Key Takeaways
- • Bedrock Robotics, an SF-based autonomous construction equipment developer, raised $600M in Series C funding at a $4.1B post-money valuation, with CapitalG and Emergence Capital leading.
- • L Catterton invested in Glance, an agentic shopping platform owned by Singapore's InMobi, according to the Axios roundup.
- • Aspen Neuroscience set IPO terms of 9.4M shares at $15-17, implying a $494M fully diluted market cap at the midpoint, with a planned Nasdaq listing under ASPE.
- • Acuity (NYSE: AYI) agreed to acquire Parameter Technologies for $675M, and Francisco Partners completed its $650M acquisition of Weave Communications.
- • Bambusa Therapeutics set IPO terms of 9.4M shares at $15-17, implying an $837M fully diluted value at the midpoint, with a planned Nasdaq listing under BBTX.
Summary
Bedrock Robotics, an San Francisco-based developer of autonomous construction equipment, raised $600 million in Series C funding at a $4.1 billion post-money valuation, according to Axios. CapitalG and Emergence Capital led the round, joined by US Innovative Technology Fund, Bessemer Venture Partners, Temasek, 8VC, Georgian, Valor Equity Partners, Xora, Eclipse, Perry Creek Capital and NVIDIA.
In private equity, L Catterton invested in Glance, an agentic shopping platform owned by Singapore's InMobi. Francisco Partners completed its $650 million acquisition of Weave Communications, a Utah-based patient engagement platform. Bertram Capital acquired Motion & Control Enterprises from Frontenac, and Kennedy Lewis acquired Roadsurfer, a Munich-based camper van rental company.
In liquidity events, Acuity (NYSE: AYI) agreed to acquire Parameter Technologies, a Fort Collins, Colo.-based developer of leak detection and monitoring systems for data centers and critical infrastructure, for $675 million. May River Capital backs Parameter. Clio acquired Page, a Washington D.C.-based government relations and regulatory intelligence platform, and Unconventional AI acquired Israeli inference optimization startup NeuReality.
In public offerings, Aspen Neuroscience, a San Diego-based developer of stem cell therapies for Parkinson's disease, set IPO terms of 9.4 million shares at $15-17, implying a $494 million fully diluted market cap at the midpoint. The Phase 1 company has raised $380 million, with OrbiMed holding a 13.1% pre-IPO stake and Arch Venture Partners holding 12.3%. Bambusa Therapeutics, a Boston-based developer of bispecific antibodies for inflammatory diseases, also set IPO terms of 9.4 million shares at $15-17, implying an $837 million fully diluted value at the midpoint, with plans to list on the Nasdaq under BBTX. The Phase 2 company has raised $142 million, with Salvia holding a 24.3% pre-IPO stake.
Other venture rounds included Nevis, an NYC-based wealth management operating system, which raised a $70 million Series B led by EQT Ventures, and Hexagon Bio, which raised $62 million in Series C led by The Column Group.
In private equity, L Catterton invested in Glance, an agentic shopping platform owned by Singapore's InMobi. Francisco Partners completed its $650 million acquisition of Weave Communications, a Utah-based patient engagement platform. Bertram Capital acquired Motion & Control Enterprises from Frontenac, and Kennedy Lewis acquired Roadsurfer, a Munich-based camper van rental company.
In liquidity events, Acuity (NYSE: AYI) agreed to acquire Parameter Technologies, a Fort Collins, Colo.-based developer of leak detection and monitoring systems for data centers and critical infrastructure, for $675 million. May River Capital backs Parameter. Clio acquired Page, a Washington D.C.-based government relations and regulatory intelligence platform, and Unconventional AI acquired Israeli inference optimization startup NeuReality.
In public offerings, Aspen Neuroscience, a San Diego-based developer of stem cell therapies for Parkinson's disease, set IPO terms of 9.4 million shares at $15-17, implying a $494 million fully diluted market cap at the midpoint. The Phase 1 company has raised $380 million, with OrbiMed holding a 13.1% pre-IPO stake and Arch Venture Partners holding 12.3%. Bambusa Therapeutics, a Boston-based developer of bispecific antibodies for inflammatory diseases, also set IPO terms of 9.4 million shares at $15-17, implying an $837 million fully diluted value at the midpoint, with plans to list on the Nasdaq under BBTX. The Phase 2 company has raised $142 million, with Salvia holding a 24.3% pre-IPO stake.
Other venture rounds included Nevis, an NYC-based wealth management operating system, which raised a $70 million Series B led by EQT Ventures, and Hexagon Bio, which raised $62 million in Series C led by The Column Group.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.